IRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate at the upcoming healthcare investor conferences. Citi BioPharma Conference Date: Wednesday, September 6 – Thursday, September 7, 2023 Location: Four Seasons, Boston, MA Baird Global Healthcare Conference Date: Tuesday, September 12 – Wednesday, September 13, 2023 Location: InterContinental New York Barclay, New York, NY Leerink Partners Biopharma Summit Date: Wednesday, September 20 – Friday, September 22, 2023 Location: Rosewood Miramar Beach, Montecito, CA Cantor Global Healthcare Conference Date: Tuesday, September 26 – Thursday, September 28, 2023 Location: InterContinental New York Barclay, New York, NY Links to the presentations will be posted on the Investors section of the Reneo Pharmaceuticals corporate website. About Reneo Pharmaceuticals Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar (REN001), is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria. For additional information, please see reneopharma.com. Contacts: Danielle Spangler Investor Relations Reneo Pharmaceuticals, Inc. dspangler@reneopharma.com Matthew Purcell, Pharm.D. Media Inquiries Russo Partners, LLC matthew.purcell@russopartnersllc.com

2023-05-31

·GlobeNewswire-Health Care

Update -- Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference

IRVINE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate at the Jefferies Healthcare Conference. Jefferies Healthcare ConferenceDate: Wednesday, June 7, 2023Location: Marriott Marquis, New York, NYPresentation: 11:00 a.m. EDT (webcast) Links to the webcast and presentation will be posted on the Investors section of the Reneo Pharmaceuticals corporate website. About Reneo PharmaceuticalsReneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar (REN001), is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria. For additional information, please see reneopharma.com. Contacts: Danielle Spangler Investor Relations Reneo Pharmaceuticals, Inc. dspangler@reneopharma.com David Melamed, Ph.D. Media Inquiries Russo Partners, LLC david.melamed@russopartnersllc.com

2023-05-31

·BioSpace

Reneo Pharmaceuticals to Participate at the 2023 Jefferies Healthcare Conference

IRVINE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate at the Jefferies Healthcare Conference. Jefferies Healthcare Conference Date: Wednesday, June 7, 2023 Location: Lotte New York Palace, New York, NY Presentation: 11:00 a.m. EDT (webcast) Links to the webcast and presentation will be posted on the Investors section of the Reneo Pharmaceuticals corporate website. About Reneo Pharmaceuticals Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar (REN001), is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria. For additional information, please see reneopharma.com. Contacts: Danielle Spangler Investor Relations Reneo Pharmaceuticals, Inc. dspangler@reneopharma.com David Melamed, Ph.D. Media Inquiries Russo Partners, LLC david.melamed@russopartnersllc.com

100 项与 REN-001 (Renovacor, Inc.) 相关的药物交易

登录后查看更多信息